3.4.22.71	additional information	aryl (beta-amino)ethyl ketones inhibit sortase enzymes. Inhibition of sortases occurs through an irreversible, covalent modification of their active site cysteine. Sortases specifically activate this class of molecules via beta-elimination, generating a reactive olefin intermediate that covalently modifies the cysteine thiol	2	
3.4.22.71	quercetin	IC50 for recombinant SrtB(DELTA30): 0.03328 mM, no antibacterial activity against Staphylococcus aureus	137	
3.4.22.71	kaempferol	IC50 for recombinant SrtB(DELTA30): 0.02455 mM, no antibacterial activity against Staphylococcus aureus	408	
3.4.22.71	myricetin	IC50 for recombinant SrtB(DELTA30): 0.03689 mM, no antibacterial activity against Staphylococcus aureus	484	
3.4.22.71	morin	IC50 for recombinant SrtB(DELTA30): 0.00854 mM, no antibacterial activity against Staphylococcus aureus	1145	
3.4.22.71	phloretin	compound shows little anti-Staphylococcus aureus activity, but significantly inhibit SrtB activity in vitro. Phloretin reduces human alveolar epithelial cell damage caused by Staphylococcus aureus. Phloretin directly localizes in the active pocket of SrtB and blocks substrate binding	1762	
3.4.22.71	isorhamnetin	IC50 for recombinant SrtB(DELTA30): 0.04335 mM, no antibacterial activity against Staphylococcus aureus	1977	
3.4.22.71	galangin	IC50 for recombinant SrtB(DELTA30): 0.03837 mM, no antibacterial activity against Staphylococcus aureus	2110	
3.4.22.71	coptisine	coptisine can bind to the active pocket of SrtB, residues Arg115, Asn116, and Ile182 play a vital role in the interaction of SrtB with coptisine. Coptisine can reduce the adhesion of Staphylococcus aureus to human lung epithelial cells	11195	
3.4.22.71	berberine chloride	potential of this inhibitor for the treatment of Staphylococcus aureus infections	23056	
3.4.22.71	beta-sitosterol-3-O-glucopyranoside	potential of this inhibitor for the treatment of Staphylococcus aureus infections	23760	
3.4.22.71	quercetin-3,3'-dimethyl ether	IC50 for recombinant SrtB(DELTA30): 0.0603 mM, no antibacterial activity against Staphylococcus aureus	23761	
3.4.22.71	galangin-3-methyl ether	IC50 for recombinant SrtB(DELTA30): 0.1136 mM, no antibacterial activity against Staphylococcus aureus	23762	
3.4.22.71	(Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile	potential of this inhibitor for the treatment of Staphylococcus aureus infections	35474	
3.4.22.71	(Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile	50% inhibition with 0.0101 mg/ml	35474	
3.4.22.71	psammaplin A1	potential of this inhibitor for the treatment of Staphylococcus aureus infections	59031